Physician profile
James A Cunningham
NPI 1912036740
$2,122.40
in general payments reported to CMS, 2019-2025
26 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $173 · 2021: $192 · 2022: $542 · 2023: $459 · 2024: $264 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.32 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.58 | 2020-2025 | Botox, Lupron Depot |
| Astellas Pharma US INC | $444.87 | 2020-2024 | Xtandi, Myrbetriq, Veozah |
| Pfizer INC. | $224.47 | 2021-2025 | |
| Allergan, INC. | $199.53 | 2019-2022 | |
| Janssen Biotech, INC. | $179.98 | 2019-2025 | Erleada |
| Coloplast Corp | $109.69 | 2023-2025 | Speedicath |
| Myovant Sciences INC. | $67.78 | 2021-2022 | |
| 180 Medical, INC. | $40.47 | 2025 | |
| Progenics Pharmaceuticals, INC. | $36.19 | 2025 | |
| Urogen Pharma, INC. | $34.02 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.30 | 2022-2023 | Quviviq |
| C. R. Bard, INC. & Subsidiaries | $31.55 | 2019-2025 | Aptra |
| Urovant Sciences INC | $29.18 | 2022 | |
| Angiodynamics, INC. | $25.83 | 2022 | |
| Genzyme Corporation | $24.92 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.07 | 2019 | |
| Axonics, INC. | $20.09 | 2022 | |
| Tactile Systems Technology INC | $19.41 | 2022 | |
| Endo Pharmaceuticals INC. | $19.39 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $18.91 | 2022 | |
| Boston Scientific Corporation | $18.14 | 2019 | |
| Stryker Corporation | $16.72 | 2023 | Revolution |
| Blue Earth Diagnostics | $16.24 | 2022 | |
| Merck Sharp & Dohme LLC | $15.40 | 2023 | Lynparza, Keytruda, Welireg |
| Alexion Pharmaceuticals, INC. | $15.15 | 2025 | Strensiq |
| Dendreon Pharmaceuticals LLC | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.